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a b s t r a c t
Disconnected cancer research data management and lack of information exchange about planned and
ongoing research are complicating the utilisation of internationally collected medical information for
improving cancer patient care. Rapidly collecting/pooling data can accelerate translational research in
radiation therapy and oncology. The exchange of study data is one of the fundamental principles behind
data aggregation and data mining. The possibilities of reproducing the original study results, performing
further analyses onexisting researchdata to generate newhypotheses or developing computationalmodels
to supportmedical decisions (e.g. risk/beneﬁt analysis of treatment options) represent just a fraction of the
potential beneﬁts of medical data-pooling. Distributed machine learning and knowledge exchange from
federateddatabases canbe considered asonebeyondother attractive approaches for knowledge generation
within ‘‘Big Data’’. Data interoperability between research institutions should be themajor concern behind
awider collaboration. Information captured in electronic patient records (EPRs) and study case report forms
(eCRFs), linked togetherwithmedical imaging and treatment planning data, are deemed to be fundamental
elements for large multi-centre studies in the ﬁeld of radiation therapy and oncology. To fully utilise the
capturedmedical information, the studydata have to bemore than just an electronic version of a traditional
(un-modiﬁable) paper CRF. Challenges that have to be addressed are data interoperability, utilisation of
standards, data quality and privacy concerns, data ownership, rights to publish, data pooling architecture
and storage. This paper discusses a framework for conceptual packages of ideas focused on a strategic
development for international research data exchange in the ﬁeld of radiation therapy and oncology.
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Background and rationale
Clinical and pre-clinical radiotherapy study data represent one
of the most valuable assets for academic radiation therapy and
oncology research institutions. Rapidly pooling research data via
the process of data exchange has become beneﬁcial and a neces-
sary requirement for conducting large multi-centre radiotherapy
studies [1]. Resulting data pools represent the primary input for
generation of medical knowledge bases with a broad range of
applications, including predictive models for decision support sys-
tems based on clinical data [2] and discovery of prognostic features
in radiomics [3]. Predictive model research has potential to not
only improve quality-of-life but also increase survival, for example
by using isotoxic strategies [4]. Fig. 1 depicts the process of an
application-speciﬁc knowledge discovery from large scale multi
centre data pools.
Integrated radiotherapy research data (originating from multi-
ple data sources) represent a powerful research tool to evaluate
dose, volume and time parameterised responses in tumours and
normal tissues. Such data are fundamental for generating novel
multivariable prediction models for tumour control probability
(TCP) and normal tissue complication probability (NTCP). These
prediction models can be translated into innovative studies on per-
sonalised radiotherapy, e.g. for biologically based intensity modu-
lated dose distributions which may reduce the risk of treatment
toxicity or increase the probability of local tumour control. As such
they can also be used to inform and involve patients in treatment
decisions through shared decision making [5]. Reliable estimates of
treatment consequences are a prerequisite for discussing patients’
preferences and for assessing their personal trade-off between the
risks and beneﬁts of treatment options. Conversely, data on patient
values and preferences can also be added to the database to
incorporate the patients’ perspectives.
The data also are extremely useful for comparative analyses of
treatment approaches, e.g. particles vs. photons or different
treatment combinations [6,7], and have the potential to decrease
health care costs with a more rational use of expensive medical
technology [8]. By linking them to investigations on tissues of
the corresponding patients, they may also provide a backbone for
the identiﬁcation and validation of (imaging) biomarkers for radi-
ation oncology. Sharing research data can accelerate the process of
medical quality assurance, including checks for consistent contour-
ing, dose (re-)planning and protocol adherence in prospective radi-
otherapeutic studies. Finally, sharing research data may speed up
the adoption of research results into day to day clinical practice.
It is the concern of translational research informatics to provide
an appropriate software solution for managing integrated research
datasets, enabling the broader collaboration of research institutions.
On 26th November 2013 a workshop organised by the German
Cancer Consortium (DKTK) and EurocanPlatform was hosted in
Dresden, Germany to examine radiotherapy-speciﬁc IT solutions
developed within Europe. Existing projects within the European
Society for Radiotherapy and Oncology (ESTRO) and several regio-
nal, national and international initiatives were presented. The
workshop resulted in two important conclusions. Firstly, the pre-
sented platforms, as diverse as they are, focus on the same set of
problems mostly on an institutional level with few examples on
a national and international dimension. Secondly, a strong interest
was stated in setting up a collaborative effort to accelerate and har-
monise the ongoing data collection activities and to promote open
access to radiotherapy research datasets.
The main goal of this paper is to initiate the development of a
radiotherapy-speciﬁc data exchange strategy preventing discon-
nected institutional level solutions and move towards interna-
tional data interoperability. This can be achieved by the
implementation of well-chosen concepts, without the need for
unnecessary reinventions.
The following major challenges that currently hamper effective
collaboration and data exchange efforts were identiﬁed:
 Interoperability between clinical IT solutions: systems differ in
their acceptance/support of internationally standardised proto-
cols, formats and semantics.
 Maturity of radiotherapy information standards: incomplete
development of radiotherapy speciﬁc data element dictionaries,
controlled vocabularies and ontologies.
 Uniformity of data collection: data are collected using different
scoring systems (e.g. scoring of radiation-induced toxicity) and
at different time points, which may render data merging com-
plicated or even impossible.
 Data completeness: data are often represented without sufﬁ-
cient meta-data, causing the risk of information loss after
exchange.
 Data quality: the quality of collected information can vary from
project to project and from institution to institution, making it
necessary to establish quality assurance work-ﬂows.
 Data bias: difference in practice, protocols and equipment may
cause a systematic difference between data from different
institutes.
 Patient privacy: the protection of privacy and the relation to
informed consent as well as secondary use of research data have
to be considered seriously, also in view of the very different
interpretation and application of conﬁdentiality and privacy
rules and laws between different countries, different states of
one country and sometimes even between different ethical
committees.
 Open source data: in disciplines like genetics there is the tradi-
tion to rely on published public repositories data. This is not the
case with most of the clinical disciplines.
These challenges impede the realisation of large scale multi-
centre exchange of medical data and leads to unnecessarily high
costs. It is unrealistic to expect an immediate and conclusive solu-
Fig. 1. Large scale multi-centre studies produce raw data pools, which can be used
to generate application-speciﬁc prediction models or knowledge bases.
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tion for the harmonisation of currently used IT research platforms.
However, without the efforts of interested researchers, their insti-
tutions and radiotherapy organisations, the goal of research data
interoperability will remain a continuing challenge and risk to fade
away in future plans for setting up studies. The recent innovations
in clinical data standardisation [9] together with the European
Commission’s data protection reform in progress [10] suggest that
now it is the ideal point of time to start to analyse and to establish
the necessary processes for multi-institutional data exchange. It
will require sincere engagement but may result in great beneﬁt
to clinical as well as translational cancer research. In future, the
interactive data bases might even be used for personalised medi-
cine by means of generating predictions on outcome for individual
patients based on analyses of their patient-tumour- and treat-
ment-related data, which would facilitate treatment choice, either
by physicians or through shared decision making. Additionally, this
initiative could be of great importance from a health economic per-
spective, by enabling evaluation of efﬁcacy and cost-beneﬁt of dif-
ferent approaches, such as new technologies and/or new combined
modality treatments.
Radiotherapy data management
For successful creation of an international data exchange strat-
egy it is necessary to understand the core principles in radiother-
apy data management. This section explains why aggregating
radiotherapy research datasets is a non-trivial task. It provides
details about different types of data pooling system architectures
and shows the importance of clinical data and metadata standardi-
sation. In addition to technical concepts it describes the role of
information technology in study quality assurance. Data protection
issues are addressed taking into account current developments of
protection laws in the EU. This section ends with a summary of
data pooling and sharing initiatives as well as software platforms
as basic for forming an initiative to unify radiotherapy data
exchange processes.
Working with radiotherapy research data
Information that is necessary to conduct research in the domain
of radiation therapy and oncology is present in various modalities
and scattered within diverse information systems. Table 1 provides
an overview of possible radiotherapy research data types with
their common information management systems [11].
These data sources need to be queried to provide complex data-
sets for comprehensive data analyses, as depicted in Supplemen-
tary Fig. 1. An international effort to promote the interoperable
exchange of DICOM images and treatment planning data has been
undertaken jointly by clinicians and equipment manufacturers
through one of the Integrating Healthcare Enterprise (IHE) initia-
tive [12] proﬁles. IHE proﬁles sit on top of existing standards and
deﬁne detailed rules/workﬂows for linking medical information
systems within an institution.
Gaining in-house clinical IT systems interoperability is impor-
tant especially with respect to the convenient creation of locally
anonymised/pseudonymised datasets. These are managed by insti-
tutional data warehouse, which provides a universal access to
aggregated research data that are afterwards discoverable under
chosen semantic model (ontology). This is why research data ware-
houses present important components for multi-centre and multi-
study data collection and analysis.
Data pooling architectures
The pooling architecture deﬁnes how the data are processed,
shared, stored and used in a speciﬁed system. It is possible to dif-
ferentiate between the following major classes of data pooling
models pictured in Fig. 2:
1. Centralised model: giving priority to full control over data,
which are logically located in a centralised repository. There is
no direct communication between institutions and all processes
happen in a central system (e.g. push/ pull transactions, audit-
ing). This leads to a simple architecture, however it raises sev-
eral questions to be solved, including data privacy and
anonymisation, independent access-control to data, Intellectual
Property (IP) rights to publish and the security risk of data accu-
mulated in one place. Advantages are that the data are centra-
lised, stored in a virtual storage (cloud data repository), and
updating of individual data is straightforward (depending on
the to-be-agreed-upon protocols).
2. Decentralised model: prioritises separation of data through
institution’s autonomous data repositories. Sharing is project-
based via direct communication of two or more institutions
without any mediator usually as export/ import jobs. Infrastruc-
ture information that is necessary to technically enable data
exchange is distributed to each location. Data can be stored
redundantly (after exchange). One of the challenges is the
required interactivity for updating of the federated data when-
ever information is added; the risk exists that several versions
of merged data exist depending on the dates when the data
exchange took place.
3. Hybrid model: tries to take the best from centralised and decen-
tralised models. The data exchange is again realised via direct
communication of two or more participating institutions. To
simplify this communication the central server is used to store
infrastructure information necessary for data exchange. The
central server can also hold the data model, controlled termi-
nologies and other necessary meta-data to enable the data
interoperability within decentralised data exchange.
Given the heterogeneity of currently used IT platforms, decen-
tralised and hybrid approaches should be considered as preferred
architectures behind a new international data exchange strategy.
Technologically even these solutions could be conﬁgured to auto-
mate the export/ exchange/ update data processes and thus hide
the complexity of the systems and provide a swift and interactive
user experience.
Table 1
Radiotherapy research data types within their common IT systems.
Information type Data examples IT
system
Baseline clinical
data
Demographics (including co-morbidity and
family history), TNM-stage, date of
diagnosis, histopathology
HIS,
TDS
Diagnostic imaging
data
Diagnostic CT, MR and PET imaging PACS
Radiotherapy
treatment
planning data
Delineation/structure sets, planning-CT,
dose matrix, beam set-up, prescribed dose
and fractions
PACS,
RIS
Radiotherapy
treatment
delivery data
Cone beam CTs, orthogonal EPID imaging,
delivered fractions
PACS,
RIS
Non-radiotherapy
treatment data
Surgery, chemotherapy HIS,
TDS
Outcome data Survival, local control, distant failure,
toxicity (including patient reported
outcomes), quality of life
EDC,
TDS
Follow-up imaging
data
Follow-up CT, MR and PET imaging PACS
Biological data Sample storage, shipping, tracing and lab
results
LIMS
Additional study
conduct data
Study design, protocol, eligibility criteria EDC,
CTMS
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Additionally in a situation, where locally collected data for
legal/ethical reasons cannot be shared with partners, distributed
solutions provide more possibilities for advanced data analysis
such as the exchange of medical knowledge/models from locally
aggregated research datasets. The ﬁnal hypothesis is then derived
from several local models reported by participating institutions.
This concept is known as ‘‘distributed learning’’ and its successful
application is presented in [13]. This principle can even be taken
one step further by setting up an ‘‘online learning’’ environment
where the master (merged) knowledge model continuously
updates (improves) as more and more patient data are available
for analysis.
Fundamental elements for data interoperability
Data interoperability is the key element for a useful data
exchange strategy. It can be described as the system’s ability to
read and understand information produced by another system.
Internationally developed standards are the starting point for
achieving interoperability. However, in a real world scenario, the
application of standards does not work as a plug-and-play solution.
It requires a complex multi-stage process which will make interop-
erability possible. First of all, data interoperability consists of two
main sub-principles:
 Syntactic interoperability: focuses on establishing common
data formats and exchange protocols. In other words syntac-
tic interoperability is unifying write/ read information
processes.
 Semantic interoperability: focuses on the proper interpretation
of the information. It ensures that the meaning of information is
not lost or changed during the data exchange process. This way
it makes the information reliable and understandable.
The structure of information in a clinical research domain can
be represented by a hierarchical pyramid as depicted in Supple-
mentary Fig. 2. It consists of several layers, where each has its place
within the process of making data interoperable.
At the bottom, a standardisation of medical terms leads to the
creation of controlled vocabularies, where terms describing medi-
cal context are deﬁned. To avoid national (linguistic) names, they
often need to have a code representation. When the relationship
between deﬁned terms is also captured (e.g. simple parent–child
relationship or more complex self-deﬁned relations) the resulting
concept is called ontology.
In the middle, there is a formalisation of descriptive information
about data ﬁelds collected within e.g. CRFs. Data ﬁelds collect
information represented as basic data type or medical terms from
controlled terminology. They also contain meta-data information
that is necessary for the data acquisition process (e.g. required
value, standardised questions, etc.)
The upper level of the information hierarchy is represented via
a concept called the information model. Within the information
model, data are composed to form complex data types represent-
ing clinical domain real world entities (e.g. study subject, study
protocol, etc.).
Achieving this level of information consistency requires sub-
stantial efforts however, it would bring a lot of advantages:
Fig. 2. Schematic drawings of centralised, decentralised and hybrid data pooling models. A centralised approach depends on a central data repository. A decentralised
solution consists of a network of sibling repository nodes. A hybrid approach combines a network of decentralised repository nodes with a central infrastructural database.
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 The model completely deﬁnes the clinical study process.
 It ensures data and metadata integrity during data exchange.
 It is time-resistant for long term storage, update and usage.
In reality there are multiple implementations of these core con-
tents, because the understanding and perception of information
differs within medical domain areas (different point of view of
healthcare, clinical research or biology experts). This sustains the
need for harmonising and linking activities to allow transparent
utilisation of multiple medical information models (see Supple-
mentary Fig. 3). One example of such initiative is the UML based
Biomedical Research Integrated Domain Group (BRIDG) model
[14] harmonising Clinical Data Interchange Standards Consortium
(CDISC) [15], Health Level 7 (HL7) [16], the U.S. Food and Drug
Administration (FDA) and the U.S. National Cancer Institute (NCI)
activities. However in view of current technological developments
the utilisation of semantic web technologies (also known as
‘‘Linked Data’’) seems to be a more ﬂexible option. The biggest
advantage of semantic web is frictionless linkage of information
across multiple information models (semantic web uses ontologi-
cal representation of information). Leading information model pro-
viders like CDISC or NCI, which understand the needs of clinical
informatics practitioners, are trying to publish their standards in
representations suitable for semantic web (using W3C Resource
Description Framework RDF speciﬁcation).
A strategy for the development, selection and utilisation of
standards has to be considered carefully for the purpose of a suc-
cessful data exchange. Application of standards on a post-facto
basis is difﬁcult, time consuming and prone to systematic as well
as random errors. That is why it is important to establish up-front
deﬁned data collection elements for broader institutional
collaboration.
Quality assurance
Information technology can support the process of quality
assurance (QA) for collected radiotherapy data. It can be used
for ‘‘real-time’’ assessment of treatment plans by peer-review or
trial centre [17]. The utilisation of standards will lead to a higher
consistency of prospectively collected data but does not automat-
ically improve data quality. Therefore, the quality control lies
within the responsibility of designated QA personnel. Correct
usage of technologies for study design and conduct should help
ensure a certain level of data quality. Information systems can
e.g. guide QA according to standardised –to be designed– proce-
dures that deﬁne the scope and rules of automatic validation
and veriﬁcation (e.g. subject cannot die before birth, automatic
body mass index calculation, etc.). Obviously the automation of
QA depends on the level of agreement on deﬁnition of such QA
procedures. Data pooling fed with low- quality data may lead to
big datasets, but their practical usability will be very limited.
One way to improve data quality is via establishment of ‘‘umbrella
protocols’’ with CRF standardisation, which can be deﬁned and
published in vendor independent human and machine readable
formats.
Ethics and regulations
Current EU data protection laws do not harmonise rules for
health related data processing [10]. The conditions for data
utilisation for research differ across countries and sometimes even
within regions of one country. This fragmentation causes major
problems for international scientiﬁc collaborations in medical
research. In addition, the interpretation and therefore application
of the same rules might lead to a varying conduct at an even
smaller scale (ethics committees, hospital).
The European Commission’s planned new data protection
reform represents a draft for a Regulation which will replace the
existing Data Protection Directive (95/46/EC) and associated Mem-
ber State legislation [18]. If approved, this reform might bring
many beneﬁts. Most importantly it will [10]:
 Unify current EU data protection rules into one regulation,
 Establish one supervised regulation authority for data
protection,
 Be applicable to institutions within as well as outside the EU
(under the provisions stipulated in Article 3),
 Take direct effect in all EU Member States (the reforms will not
have to be transposed) [18].
The original draft Regulation included a requirement for speciﬁc
and explicit consent for the use and storage of personal data, but
provided an exemption for research, subject to certain safeguards
in Article 83. The European Parliament’s amendments to Articles
81 (Processing of personal data concerning health) and 83 (Pro-
cessing for historical, statistical and scientiﬁc research purposes)
substantially reduce the scope of this research exemption. This
means, if implemented in the current version, that the use of per-
sonal data in research without speciﬁc consent would be prohib-
ited or become impossible in practice [19], which is indeed a
major issue for cancer research and even for quality assurance. In
practice each patient (or after death his/her relatives), even when
the patient has signed general informed consent for scientiﬁc eval-
uation of the data, would need to be re-consented each time a new
scientiﬁc project is started. On the other hand once a speciﬁc
informed consent is present, it will be valid throughout the entire
EU. Another provision is that the ‘‘right to be forgotten’’ [20] does
not apply to scientiﬁc research sectors [10].
Because of the possible threat to performing (clinical) research
in the EU, a position paper in Annals of Oncology [21] was
published authored by the European Society for Medical Oncology
(ESMO), endorsed by the European CanCer Organisation (ECCO),
the European Cancer Patient Coalition (ECPC), the European Middle
Eastern & African Society for Biopreservation and Biobanking
(ESBB), the European Organisation for Research and Treatment of
Cancer (EORTC), the EurocanPlatform, the European Society of
Paediatric Oncology (SIOPE), the European Society for
Radiotherapy & Oncology (ESTRO), the European Society of Surgical
Oncology (ESSO) and the Association of European Cancer Leagues
(ECL).
An alternative for international data pooling would be complete
anonymisation of patient data. Anonymised patient data are not
within the material scope of the Regulation. The problem lies in
the fact that anonymised patient data may not be possible as more
data elements are being shared on an individual patient.
Data pooling and sharing initiatives
Research and development across the ﬁeld of medical and clin-
ical informatics is very active including several ongoing data col-
lection and exchange initiatives. Some of these initiatives are
providing open access to their deliverables in the form of applica-
tion platforms, terminologies, guidelines and collected data. It is
wise to consider them and if possible to build on them to leverage
the experience and already invested resources. Supplementary
Table 1 provides a partial overview of software systems used for
research data and metadata management [22,23]. Some of these
platforms are released as freeware or under open source licenses
which make them affordable for all academic research institutions.
The selection of existing initiatives and research databases in the
ﬁeld of radiation therapy and oncology is presented in Supplemen-
tary Table 2 [24–29]. When deﬁning a common data exchange
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strategy in radiotherapy it is necessary to consider involvement of
existing initiatives in order to gain broader acceptance.
The next steps for data exchange in radiotherapy
From the information summarised above, it is apparent that it is
timely now to initiate broader collaboration for radiotherapy data
exchange. Present information technology innovations offer
advanced methods for establishing data interoperability and for
accelerating the data pooling process. However, the commitment
of cancer research institutions is necessary to trigger and harbour
the activities that will lead to a formal deﬁnition of the data
exchange strategy.
This paper would like to promote an agile solution for establish-
ment of a standard data exchange. Agile work is characterised via
continuous iterative delivery and validation by prototypes. An
international ‘‘dummy run’’ can be set up as a test case/prototype
for evaluating the robustness of the data exchange strategy and
is foreseen between several of the partners that participated in
the workshop. It can also be used as a testing case for each
participating institution to prove whether the exchange strategy
speciﬁcation criteria have been met. A simpliﬁed working plan is
depicted in Fig. 3.
The commitment and engagement of professionals is manda-
tory to establish the collaboration model between clinicians, phys-
icists, IT, legal/ethics personnel of the participating institutions
(including several other specialisations if available like mathemati-
cians, statisticians etc.). Within the interdisciplinary and inter-
institutional cooperation, the medical group professionals will
design the set-up of a dummy study for radiotherapy. Initially, it
should be minimalistic (with relatively small numbers of patient
records) but complete regarding data types necessary for research
in radiotherapy. The medical group also has to harmonise data col-
lection elements. A good start can be e.g. utilisation of CRF harmo-
nisation activities from NCI [30] and/or by using the validated
terminology proposed by the Global Harmonisation Group and/or
using the Linked Data principle. An IT group will analyse currently
used IT platforms to ﬁnd common characteristics across the insti-
tutions and deﬁne technological solutions that should be proposed
for the data exchange strategy. The output should cover aspects
like data formats and communication protocols. A legal/ethics
group will summarise the pre-conditions necessary to exchange
and pool clinical data in compliance with national laws.
Fig. 3. Simpliﬁed working scheme for the creation of a data exchange strategy. The ﬁrst step is formation of working groups that will prepare a draft strategy. The next step is
the implementation of the proposed strategy by participating institutions followed by a dummy run. Finally, the data exchange strategy is ofﬁcially released with all
documentation and guidelines.
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The outcome of this preliminary step will be processed into the
ﬁrst proposal for a data exchange strategy. This standard document
will formally deﬁne the data sharing process with exact speciﬁca-
tion of data elements, their coding, storage data format and
exchange communication protocols. It will formally deﬁne and
describe import/export scenarios. Implementation of these within
the institution’s environment will allow the institution to partici-
pate in a test run of the dummy study.
After completion of the test, each institution should have one
big pooled dataset locally at its site.
The deliverables resulting from the development of the data
exchange strategy (in the form of software, documentation, guide-
lines, data etc.) will be hosted and openly available for all partici-
pating institutions. As soon as the ﬁrst version of the strategy is
created a strategy maintenance process will be established to keep
strategy elements (e.g. data element repositories) up to date.
With the ﬁrst aggregated big data pools are in place, an initia-
tive dedicated to data knowledge extraction and biomedical mod-
elling will start in order to develop dedicated decision support
tools. Furthermore establishing open public access to data pub-
lished under DOI data (approach very successfully used in genetics)
will make reusing a research data straightforward and as such will
stimulate research in radiation oncology.
Conclusion
Creating a robust and usable radiotherapy speciﬁc data
exchange strategy is challenging but feasible. It requires invest-
ments and full commitment of participating institutions. However
such a strategy is a fundamental prerequisite to enable multi-cen-
tric pooling of cancer research data into common well understand-
able and reusable datasets. This process will allow seamless
collaboration on large-scale international studies and computer-
aided analysis of the large amount of high quality clinical research
data and will be the basis for rapid knowledge generation in the
ﬁeld of radiotherapy.
The data exchange strategy should be thought of as an evolu-
tionary process where the baseline for collaboration could be
exchange of standardised study protocols, data element deﬁnitions
and clinical or study data together with imaging and treatment
plans and rendering open public datasets. The complexity can be
gradually increased over time e.g. by allowing information from
local knowledge bases to be part of the exchange processes.
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